Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Hypertension and Dyslipidemia Participation in this study is possible only if all of the below are satisfied. 1. Patients who provide written consent on the consent form for use of personal information after listening to explanations regarding the purpose, method, etc. of this study 2. Adult males and females aged 19 years or above 3. Patients who correspond to one of the following: 1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia 2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin 3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin 4. The following test results available within 4 weeks prior to the enrollment date Total Cholesterol (TC) HDL-C ③ Triglyceride (TG) ④ LDL-C or LDL-C (Friedewald formula*) non-HDL-C (Total cholesterol HDL-C (mg/dL)) *LDL-C = Total cholesterol HDL-C (triglyceride/5) (mg/dL)  Patients cannot participate in this study if any of the following is applicable. 1. Contraindication according to the drug labeling of the combination drug ingredients (fimasartan, amlodipine) for hypertension containing fimasartan 2. Contraindication according to the drug labeling of statins (rosuvastatin, atorvastatin) 3. Secondary hypertension or suspected secondary hypertension Aortic coarctation, hyperaldosteronemia, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome, polycystic kidney disease, etc. 4. Secondary dyslipidemia or suspected secondary dyslipidemia Nephrotic syndrome, dysproteinemia, obstructive liver disease, Cushing's syndrome, etc. 5. Patients currently hospitalized or scheduled to be hospitalized 6. If an investigational drug has been administered within 12 weeks of the enrollment date, or if participation in another clinical study during this study participation period is planned 7. Patients who are deemed ineligible for study participation at the discretion of the investigators for other reasons -